New Delhi, July 9 -- Contract research, development and manufacturing organization (CRDMO) Anthem Biosciences, which will launch its Rs.3,395 crore initial public offering (IPO) next week, is banking on geopolitical tailwinds as global pharma companies move away from China, to unlock value and growth, the company's management told Mint in an interview on Wednesday.

"The good news is that.China is a behemoth. So we have that much headroom to grow," Ajay Bhardwaj, managing director and chief executive officer, said. "At this point, I believe that we are at a very good inflection point," said Bhardwaj, adding that the company had seen an increase in requests for proposals (RFPs) from global pharma companies.

Additionally, the company has 1...